Vesugen (20MG)

What Is Vesugen?

Vesugen (also designated T-38 in the Khavinson research program) is a synthetic tripeptide bioregulator with the amino acid sequence Lysine-Glutamic Acid-Aspartic Acid (Lys-Glu-Asp, abbreviated KED). It belongs to the Khavinson peptide series—a family of short-chain peptides developed through research on tissue-specific bioregulators at the St. Petersburg Institute of Bioregulation and Gerontology. Researchers originally identified Vesugen from vascular wall tissue extracts and designed it as a synthetic analog for investigating vascular endothelial function and regulation.

As a tripeptide—a peptide composed of exactly three amino acids—Vesugen has attracted research interest for its proposed ability to penetrate cellular and nuclear membranes to interact directly with DNA and histone proteins, thereby modulating gene expression through epigenetic mechanisms. Researchers classify Vesugen as a tissue-specific bioregulator targeting vascular endothelium, meaning it may influence cellular processes through chromatin-level gene regulation rather than through classical receptor-mediated signaling. For those looking to buy Vesugen in Switzerland, Core Peptides offers high-quality research-grade material for laboratory applications.

Vesugen Research Overview

Vesugen represents a well-characterized peptide bioregulator within the Khavinson research program, specifically designated as a vascular-targeted bioregulator. The peptide’s design—a simple tripeptide sequence of lysine, glutamic acid, and aspartic acid—belies its proposed biological activity. Researchers have investigated Vesugen primarily for its tissue-specific effects on vascular endothelial-derived experimental systems, with implications for understanding endothelial cell function, vascular tissue maintenance, and age-related vascular changes.

Research interest in Vesugen centers on its ability to modulate gene expression and support endothelial cell homeostasis in the vascular system. Studies have demonstrated that Vesugen penetrates cell nuclei and interacts with DNA, potentially modulating gene expression linked to vascular endothelial function. Specifically, Vesugen may influence the expression of genes involved in endothelial cell proliferation, SIRT1 modulation, and vascular tone regulation.

When researchers choose to buy Vesugen in Switzerland for laboratory studies, they gain access to a compound that may help elucidate mechanisms of vascular endothelial bioregulation, gene expression modulation, and epigenetic regulation at the molecular level.

How Does Vesugen Work?

Vesugen exerts its proposed biological effects through multiple interconnected pathways, including chromatin-level gene regulation, DNA interaction, and tissue-specific gene modulation. The peptide’s mechanism involves several well-characterized steps.

DNA Binding and Epigenetic Regulation

Vesugen’s primary proposed mechanism involves penetration of cellular and nuclear membranes to interact directly with DNA. Research suggests that Vesugen may bind to specific DNA sequences in the minor groove of DNA, forming hydrogen bonds with specific DNA base pairs. This interaction may influence chromatin condensation states and gene expression patterns.

Endothelial Cell Proliferation and Ki-67 Regulation

Vesugen is studied as a vascular-directed short-peptide probe, used to examine how a minimal defined peptide signal influences transcriptional, proteomic, and proliferation endpoints in vascular-derived cell populations.

Research indicates that Vesugen may stimulate the proliferation marker Ki-67, which declines with age, and may reduce apoptosis (decreased p53), thereby supporting endothelial cell renewal and vascular-tissue gene-expression programs. This mechanism may be particularly relevant in addressing age-related vascular function problems.

Neuroprotective and Geroprotective Effects

Beyond its vascular applications, Vesugen has also been explored for its neuroprotective and geroprotective consequences. Studies have examined its effects on neuron survival and morphology, suggesting its possible role in combating neurodegenerative diseases and enhancing neuroplasticity. In a 5xFAD Alzheimer’s mouse model study, KED was co-tested with EDR (Pinealon), with molecular docking predicting KED binding to promoter regions of AD-relevant genes including CASP3, NES, GAP43, APOE, SOD2, PPARA, and PPARG.

Researchers who buy Vesugen in Switzerland for research purposes can investigate these mechanisms across diverse experimental models of vascular biology, endothelial function, and gene expression modulation.

Why Is Vesugen Studied?

Researchers study Vesugen primarily for its potential relevance to vascular endothelial biology, cardiovascular tissue maintenance, and age-related vascular changes. The peptide’s ability to modulate gene expression and support endothelial cell homeostasis makes it a valuable tool for understanding the molecular basis of tissue-specific bioregulation and epigenetic mechanisms.

Vesugen has been investigated in the context of vascular and endothelial function. The peptide is specifically designed to support vascular endothelial cells, with research indicating potential applications for cardiovascular tissue maintenance in aging. Studies have explored its effects on endothelial cell proliferation, vascular tone regulation, and tissue blood flow.

Moreover, researchers study Vesugen in the context of age-related vascular changes. As vascular endothelial function naturally declines with age, understanding mechanisms that support tissue homeostasis has become increasingly important. Vesugen represents one well-documented avenue of research inquiry in this area.

Researchers who buy Vesugen in Switzerland from Core Peptides can incorporate this peptide into their studies on vascular endothelial bioregulation, gene expression modulation, and age-related vascular research.

Vesugen Research Areas

Research Area	Description
Vascular Endothelial Function	Investigating Vesugen’s effects on endothelial cell proliferation and vascular tissue maintenance
Gene Expression Modulation	Studying Vesugen’s interaction with DNA and modulation of gene expression in vascular cells
Epigenetic Regulation	Exploring Vesugen’s proposed epigenetic mechanisms of gene expression modulation
Cardiovascular Research	Examining Vesugen’s effects on cardiovascular tissue and vascular tone regulation
Endothelial Cell Proliferation	Investigating Vesugen’s stimulation of Ki-67 and endothelial cell renewal
Neuroprotection	Preclinical research into Vesugen’s neuroprotective effects in neuronal models
SIRT1 Modulation	Studying Vesugen’s effects on SIRT1 expression and protein synthesis
Age-Related Vascular Research	Exploring Vesugen’s potential relevance to age-related vascular changes

Scientific Research on Vesugen

Researchers have conducted scientific studies on Vesugen in both in vitro and preclinical settings, deriving evidence from cell cultures, preclinical models, and limited clinical research. The peptide originates from the Khavinson research program, which has investigated tissue-specific peptide bioregulators for several decades.

In Vitro Evidence

In vitro studies using fluorescence-labeled peptides have demonstrated that Vesugen penetrates cell nuclei and interacts with DNA. Research has shown that Vesugen may bind to specific DNA sequences in the minor groove, forming hydrogen bonds with specific DNA base pairs.

Furthermore, research has demonstrated that Vesugen interacts with chromatin and may modulate gene expression linked to vascular endothelial function. The peptide’s ability to penetrate both cell and nuclear membranes supports its proposed mechanism of direct nuclear interaction.

Studies have shown that Vesugen stimulates the proliferation marker Ki-67 (which declines with age) and reduces apoptosis (decreased p53), used experimentally to study endothelial cell renewal and vascular-tissue gene-expression programs.

Preclinical Studies

In animal models, researchers have investigated Vesugen’s effects on vascular function and aging. The vasoprotective effect of Vesugen, previously revealed in elder people, can be manifested through epigenetic regulation of the Ki-67 gene expression.

In a 5xFAD Alzheimer’s mouse model study, KED was co-tested with EDR (Pinealon). Molecular docking predicted KED and EDR binding to promoter regions of AD-relevant genes including CASP3, NES, GAP43, APOE, SOD2, PPARA, and PPARG.

Research has also explored Vesugen’s effects on endothelial cell proliferation and differentiation in vascular tissue studies.

Human Research

Vesugen has limited human clinical evidence. No published clinical studies were found on PubMed for Vesugen. Evidence is limited to preclinical research or theoretical mechanisms. The peptide has not achieved pharmaceutical registration in Western countries and is primarily available as a research compound. No clinical trials are registered on ClinicalTrials.gov, and no Western regulatory agency has evaluated Vesugen for any therapeutic indication.

Nevertheless, researchers should note that Vesugen is supplied for laboratory research purposes only. Scientists who buy Vesugen in Switzerland should remain aware of these evidence considerations.

Vesugen Compared With Related Peptides

Peptide	Relationship to Vesugen	Key Differences
Vilon (KE)	Shares the N-terminal two residues	Vilon is a dipeptide (Lys-Glu) targeting thymus/immune system; Vesugen (Lys-Glu-Asp) targets vascular endothelium
Prostamax (KEDP)	Shares the N-terminal three residues of Vesugen	Vesugen (KED) is the N-terminal three residues of Prostamax (KEDP); Prostamax targets prostate tissue; Vesugen targets vascular endothelium
Testagen (KEDG)	Shares the KED core sequence	Testagen has glycine at C-terminus targeting testicular tissue; Vesugen (KED) is the tripeptide precursor
Livagen (KEDA)	Shares the KED core sequence	Livagen has alanine at C-terminus targeting liver tissue; Vesugen (KED) is the tripeptide precursor
Vesilut (ED)	Both are Khavinson bioregulators	Vesilut (Glu-Asp) targets bladder and urinary tract; Vesugen (Lys-Glu-Asp) targets vascular endothelium

Research Applications

Researchers utilize Vesugen in a variety of laboratory research applications, primarily in the fields of vascular biology, endothelial research, and tissue-specific gene regulation. Key research applications include:

• Vascular Endothelial Studies: Investigating Vesugen’s effects on endothelial cell proliferation and vascular tissue maintenance
• Gene Expression Research: Exploring Vesugen’s interaction with DNA and modulation of gene expression in vascular cells
• Epigenetic Research: Studying Vesugen’s proposed epigenetic mechanisms of gene expression modulation
• Cardiovascular Research: Examining Vesugen’s effects on cardiovascular tissue and vascular tone regulation
• Endothelial Cell Proliferation Studies: Investigating Vesugen’s stimulation of Ki-67 and endothelial cell renewal
• Neuroprotection Research: Preclinical research into Vesugen’s neuroprotective effects in neuronal models
• SIRT1 Modulation Studies: Studying Vesugen’s effects on SIRT1 expression and protein synthesis
• Age-Related Vascular Research: Exploring Vesugen’s potential relevance to age-related vascular changes

Researchers who buy Vesugen in Switzerland can incorporate this peptide into their experimental protocols across these diverse research areas.

Vesugen Product Specifications

Specification	Detail
Product Name	Vesugen (KED tripeptide)
Amount	20mg
Form	Lyophilized powder
Sequence (One-Letter)	KED
Sequence (Three-Letter)	Lys-Glu-Asp
Molecular Formula	C15H26N4O8
Molecular Weight	Approximately 390.39 g/mol
CAS Number	Not assigned in public literature
PubChem CID	87571363
Synonyms	KED, Lys-Glu-Asp, T-38, vascular bioregulator peptide
Designation	T-38 in Khavinson program
Purity	>99% (HPLC)
Research Category	Cellular Research & Signaling
Storage	Store desiccated at -20°C, protected from light

How to Evaluate Vesugen Quality

When sourcing Vesugen for research purposes, researchers should consider several quality indicators. A reliable Vesugen peptide supplier should provide:

• Identity Confirmation: Analytical verification that the peptide matches the expected sequence (Lys-Glu-Asp, KED) and molecular weight (approximately 390.39 g/mol)
• Purity Analysis: Documentation of purity through methods such as HPLC – research grade typically provides >99% purity
• Batch Information: Clear lot numbers and batch traceability
• Certificate of Analysis (CoA): Documentation of analytical testing results
• Proper Labeling: Accurate product identification and storage instructions
• Appearance: White to off-white lyophilized powder
• Solubility: Soluble in water and buffered aqueous solutions

Researchers looking to buy Vesugen in Switzerland should seek suppliers who provide comprehensive documentation and quality assurance. Core Peptides remains committed to supporting research with properly documented products.

Understanding the Certificate of Analysis

A Certificate of Analysis (CoA) provides analytical data for a specific batch of a research peptide. For Vesugen research, a CoA typically includes:

• Identity Confirmation: Mass spectrometry or other analytical methods confirming the peptide’s identity
• Purity Assessment: HPLC chromatograms showing the purity of the peptide
• Batch/Lot Information: Unique identifiers for traceability
• Analytical Methods: Description of the testing methods used

Importantly, researchers should understand that a CoA demonstrates the chemical identity and purity of a peptide but does not establish safety, efficacy, therapeutic effectiveness, or suitability for human use. The CoA serves as a quality control document for research purposes only.

Storage and Stability

Proper storage of research peptides is essential for maintaining their integrity and stability. For Vesugen, researchers should refer to the product documentation provided with their order for specific storage recommendations.

General best practices for Vesugen storage include keeping the lyophilized peptide desiccated, protected from light, and stored at -20°C or below. The peptide is soluble in water and buffered aqueous solutions. For specific temperature requirements and reconstitution protocols, consult the applicable product documentation or contact Core Peptides for the applicable storage specifications.

Research Considerations

Researchers incorporating Vesugen into their studies should be aware of several important considerations:

• Evidence Limitations: Vesugen has limited human clinical evidence. No published clinical studies were found on PubMed for Vesugen. Evidence is limited to preclinical research or theoretical mechanisms.
• Experimental Status: Researchers consider Vesugen an experimental compound. Therefore, findings should be interpreted within the context of early-stage research.
• Model Differences: Results from cell cultures, organotypic explant cultures, and preclinical models may not translate directly to complex biological outcomes.
• Regulatory Status: Vesugen has not achieved pharmaceutical registration in Western countries and is intended for laboratory research use only.
• Quality Considerations: Researchers should verify the quality and identity of their Vesugen through appropriate analytical methods.
• Mechanistic Context: Vesugen’s proposed mechanisms involve chromatin-level gene regulation, DNA interaction, and tissue-specific gene modulation. Researchers should consider appropriate experimental approaches to investigate these pathways.
• Tissue Specificity: Vesugen demonstrates tissue-specific effects on vascular endothelial-derived experimental systems. Researchers should consider this specificity when designing experiments.

Researchers who buy Vesugen in Switzerland should ensure their studies include appropriate controls and interpret findings with scientific rigor.

Frequently Asked Questions About Vesugen

What is Vesugen?

Vesugen is a synthetic tripeptide bioregulator with the amino acid sequence Lysine-Glutamic Acid-Aspartic Acid (Lys-Glu-Asp, KED), developed within the Khavinson peptide research program as a vascular-targeted bioregulator.

What is Vesugen researched for?

Researchers primarily investigate Vesugen for its effects on vascular endothelial function, gene expression modulation, endothelial cell proliferation, cardiovascular tissue maintenance, and age-related vascular changes.

What is the amino acid sequence of Vesugen?

The amino acid sequence of Vesugen is Lys-Glu-Asp (KED).

What is the molecular weight of Vesugen?

The molecular weight of Vesugen is approximately 390.39 g/mol.

What is the molecular formula of Vesugen?

The molecular formula of Vesugen is C15H26N4O8.

What is the proposed mechanism of Vesugen?

Vesugen is proposed to penetrate cellular and nuclear membranes to interact directly with DNA, thereby modulating gene expression through epigenetic mechanisms at the chromatin level. It may regulate Ki-67 expression, SIRT1, and endothelin-1 in vascular endothelial cells.

Can I buy Vesugen in Switzerland?

Yes, researchers can buy Vesugen in Switzerland from Core Peptides for laboratory research purposes.

What is the primary research category for Vesugen?

Vesugen belongs to the Cellular Research & Signaling category, with secondary relevance to Anti-Aging & Longevity research.

What related peptides are studied alongside Vesugen?

Related peptides from the Khavinson series include Vilon (KE), Prostamax (KEDP), Testagen (KEDG), Livagen (KEDA), and Vesilut (ED).

What is the purity of Core Peptides’ Vesugen?

Core Peptides provides Vesugen with a purity of >99% as verified by HPLC analysis.

Is Vesugen soluble in water?

Yes, Vesugen is soluble in water and buffered aqueous solutions.

Related Research Peptides

Researchers interested in Vesugen may also find the following related peptides relevant to their work:

• Vilon (KE) – A Khavinson dipeptide (Lys-Glu) targeting thymus/immune system
• Prostamax (KEDP) – A Khavinson tetrapeptide (KEDP) targeting prostate tissue; shares Vesugen’s N-terminal three residues
• Testagen (KEDG) – A Khavinson tetrapeptide targeting testicular tissue
• Livagen (KEDA) – A Khavinson tetrapeptide targeting liver tissue
• Vesilut (ED) – A Khavinson dipeptide (Glu-Asp) targeting bladder and urinary tract

For a comprehensive selection of research peptides in Switzerland, explore the Core Peptides catalog.

Explore Cellular Research & Signaling Peptides

Vesugen is part of our Cellular Research & Signaling category, which features a range of research peptides investigated for their effects on cellular function, gene expression, and signaling pathways. Browse our selection to find the right peptides for your laboratory research.

Explore Related Research Categories

Researchers may also find the following related categories relevant to Vesugen research:

• Anti-Aging & Longevity – Peptides investigated for age-related vascular research applications
• Cognitive & Nootropic Peptides – Peptides studied for neurological and cognitive research
• Healing & Regeneration Peptides – Peptides investigated for tissue repair and regeneration

Further Research

Researchers interested in learning more about Vesugen and related peptides should consult the primary scientific literature. Key areas of investigation include chromatin remodeling, vascular endothelial bioregulation, gene expression modulation, and tissue-specific regulation. The PubMed database is an excellent resource for accessing peer-reviewed research articles on these topics.

Research Disclaimer

Core Peptides supplies Vesugen as a research peptide for laboratory research purposes only. All information provided is for educational and scientific reference purposes only and does not constitute medical advice. Researchers are responsible for ensuring compliance with all applicable laws and regulations governing the use of research peptides in their jurisdiction, including Switzerland.